R1 RCM INC (RCM)
(Delayed Data from NSDQ)
$12.61 USD
+0.12 (0.96%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $12.60 -0.01 (-0.08%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth F Momentum D VGM
Brokerage Reports
0 items in cart
R1 RCM Inc. [RCM]
Reports for Purchase
Showing records 41 - 60 ( 201 total )
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
2023 Life Sciences & MedTech Investor Forum: Key Takeaways
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Healthcare IT: Proprietary Healthcare Credit Card Transaction Data
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
4Q Beat + 2023 Guide Reiterated; Seeing Increased Demand for Solutions
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Remain Overweight w/ $20 Target; Cloudmed Could Provide Upside in Our View
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Healthcare IT: Recap from Large HC Industry Conference
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
Company: R1 RCM Inc.
Industry: Financial - Miscellaneous Services
2023 Revenue Guidance in Line & Adj. EBITDA 3.5% Above Consensus; Cloudmed Employees to Take Leadership Positions
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department